IPHA (IPHA) Stock Price & Analysis
IPHA (IPHA) rose 1.14% to USD 1.78 as of July 25, 2026 at 10:03 UTC, according to Nexqual real-time market data.
IPHA last closed at USD 1.76; the session ranged USD 1.78–1.81 on volume of 2,306 shares. Market capitalization is $167.15M, with a 52-week range of USD 1.17–2.63 (NMS). Source: Nexqual, July 25, 2026 at 10:03 UTC.
Key Statistics (as of July 25, 2026 at 10:03 UTC)
| Price | USD 1.78 |
|---|---|
| Change | ▲ 1.14% (up) |
| Previous Close | USD 1.76 |
| Open | USD 1.81 |
| Day Range | USD 1.78 – 1.81 |
| 52-Week Range | USD 1.17 – 2.63 |
| Volume | 2,306 shares |
| Market Cap | $167.15M |
| Exchange | NMS |
Technical Analysis (IPHA)
Nexqual's technical model rates IPHA "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 10:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.66 (neutral) |
| vs SMA50 | Below (USD 1.82) |
| MACD | -0.01 (negative) |
Analyst Ratings (IPHA)
Wall Street analysts rate IPHA "None" based on 4 analysts, with a mean price target of USD 6 (range USD 3–8), per Nexqual as of July 25, 2026 at 10:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 6 |
| High Target | USD 8 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (IPHA)
| Next Earnings Date | 2026-09-17 |
|---|---|
| Revenue Estimate | $2.60M |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Financials & Fundamentals (IPHA)
| Total Revenue | $9.01M |
|---|---|
| Revenue Growth (YoY) | -46.70% |
| Gross Margin | +0.00% |
| Operating Margin | -689.55% |
| Profit Margin | +0.00% |
| Current Ratio | 1.28 |
| Total Cash | $34.31M |
| Total Debt | $22.57M |
| Free Cash Flow | $-34.07M |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Financial Health Score (IPHA)
Nexqual rates IPHA's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 10:03 UTC.
| Growth | Critical — Revenue -55% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $34M cash vs $23M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$34M, burning cash |
| Efficiency | Mixed — No data |
Ownership (IPHA)
| Insider Ownership | +1.67% |
|---|---|
| Institutional Ownership | +0.45% |
| Shares Outstanding | 93.90M |
| Float | 70.54M |
| Short % of Float | +0.18% |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Leadership (IPHA)
IPHA is led by Jonathan E. Dickinson B.Sc. (age 57), CEO & Director, per Nexqual as of July 25, 2026 at 10:03 UTC.
| CEO & Director | Jonathan E. Dickinson B.Sc. (age 57) |
|---|---|
| Executive VP & COO | Yannis Morel (age 52) |
| Senior VP & CFO | Frederic Lombard (age 50) |
| Vice President of Investor Relations, Communication & Commercial Strategy | Stephanie Cornen (age 38) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc. | USD 2.61 | ▼ 1.32% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.72 | ▲ 0.54% |
| GRTXD | Galera Therapeutics, Inc. | USD 17.5 | ▲ 7.64% |
| BYSI | BeyondSpring, Inc. | USD 1.12 | ▼ 0.88% |
| ZIVO | Zivo Bioscience, Inc. | USD 5 | ▲ 25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:03 UTC. This page is informational and not investment advice.